

Kate D Sutherland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5962367/publications.pdf>

Version: 2024-02-01

30
papers

2,287
citations

471509

17
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

4254
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung. <i>Cancer Cell</i> , 2011, 19, 754-764.	16.8	428
2	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	16.8	359
3	Multiple cells-of-origin of mutant K-Ras ⁺ induced mouse lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4952-4957.	7.1	205
4	SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. <i>Cancer Cell</i> , 2016, 30, 519-532.	16.8	178
5	Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. <i>Cell Metabolism</i> , 2018, 27, 935-943.e4.	16.2	167
6	Cell of origin of lung cancer. <i>Molecular Oncology</i> , 2010, 4, 397-403.	4.6	153
7	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 37-54.e9.	16.8	138
8	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119
9	Rapid target gene validation in complex cancer mouse models using re ⁺ derived embryonic stem cells. <i>EMBO Molecular Medicine</i> , 2014, 6, 212-225.	6.9	78
10	Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 4190.	12.8	73
11	Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis. <i>Genes and Development</i> , 2015, 29, 1587-1592.	5.9	63
12	Glutaminase inhibition impairs CD8 T ⁺ cell activation in STK11-/Lkb1-deficient lung cancer. <i>Cell Metabolism</i> , 2022, 34, 874-887.e6.	16.2	55
13	Harnessing Natural Killer Immunity in Metastatic SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1507-1521.	1.1	50
14	Keap1-Nrf2 pathway: a lid on lung cancer. <i>Cell Cycle</i> , 2018, 17, 1696-1707.	2.6	39
15	Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway. <i>PLoS Biology</i> , 2017, 15, e2000731.	5.6	37
16	Cellular Mechanisms Underlying Intertumoral Heterogeneity. <i>Trends in Cancer</i> , 2015, 1, 15-23.	7.4	36
17	Killing SCLC: insights into how to target a shapeshifting tumor. <i>Genes and Development</i> , 2022, 36, 241-258.	5.9	26
18	Lung morphogenesis is orchestrated through Grainyhead-like 2 (Grhl2) transcriptional programs. <i>Developmental Biology</i> , 2018, 443, 1-9.	2.0	21

#	ARTICLE	IF	CITATIONS
19	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. <i>Oncogene</i> , 2018, 37, 6096-6104.	5.9	10
20	Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer. <i>Methods in Molecular Biology</i> , 2018, 1725, 15-29.	0.9	9
21	Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. <i>Cell Death and Disease</i> , 2020, 11, 877.	6.3	7
22	Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis. <i>Cell Death and Differentiation</i> , 2022, 29, 96-104.	11.2	7
23	The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression. <i>Respiratory Research</i> , 2015, 16, 67.	3.6	6
24	Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy. <i>European Journal of Immunology</i> , 2020, 50, 1871-1884.	2.9	6
25	Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma. <i>Oncogene</i> , 2020, 39, 5177-5186.	5.9	5
26	NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 38, 17-20.	16.8	3
27	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2788-2805.	2.8	3
28	Characterization of a novel human BFL-1-specific monoclonal antibody. <i>Cell Death and Differentiation</i> , 2020, 27, 826-828.	11.2	2
29	Delineating the roles of Grhl2 in craniofacial development through tissue-specific conditional deletion and epistasis approaches in mouse. <i>Developmental Dynamics</i> , 2021, 250, 1191-1209.	1.8	2
30	Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1106-1109.	1.1	1